ProsTIC Theranostics: 2025 Cancer Insights & Advances

The field of prostate cancer treatment is undergoing a rapid evolution, driven by advances in theranostics – the combination of targeted therapy and diagnostic imaging. A new post from Michael Hofman, Director of the ProsTIC Theranostics program at Peter MacCallum Cancer Centre, details an extraordinarily productive 2025, showcasing not just incremental progress, but potentially paradigm-shifting results. This isn’t simply about new tools; it’s about a fundamental shift towards personalized, precision medicine in a disease that affects millions globally. The program’s success is attracting significant investment and international attention, positioning Australia at the forefront of this critical area of oncology.

For context, Prostate Specific Membrane Antigen (PSMA) is a protein found on the surface of most prostate cancer cells. Theranostics targeting PSMA utilize a radioactive tracer to both image the cancer (diagnosis) and deliver targeted radiation therapy. The challenge has been optimizing the radioactive isotope and delivery method to maximize efficacy and minimize side effects. The VIOLET study’s use of Terbium-161 is particularly noteworthy, as it’s a dual beta/Auger emitter, potentially offering a different radiation profile than the more commonly used Lutetium-177. The AlphaBet trial builds on existing Lutetium-177 PSMA therapy by combining it with Radium-223, another alpha-emitting radiopharmaceutical, aiming to enhance treatment response. This combination approach reflects a broader trend in oncology towards synergistic therapies.

The installation of the first GE Healthcare Omni 128 cm Total-Body PET scanner at Peter Mac is a game-changer. Total-body PET imaging allows for faster scans, lower radiation doses, and improved image quality, enabling more accurate diagnosis and treatment monitoring. The fact that over 11,500 scans were performed in a single year underscores the immediate impact of this technology. Furthermore, the program’s focus on liquid biomarkers, specifically ctDNA, to predict treatment response is crucial. Identifying patients who are most likely to benefit from Lu-PSMA therapy will be essential for optimizing treatment strategies and reducing unnecessary exposure to radiation.

The Forward Look: 2026 promises to be a pivotal year. The PRIMARY2 trial results will be closely watched, as they have the potential to establish PSMA PET imaging as a standard of care in prostate cancer management. Hofman’s upcoming sabbatical at Memorial Sloan Kettering Cancer Center signals a deliberate effort to foster international collaboration and accelerate the translation of ProsTIC’s findings to a wider audience. Expect to see increased partnerships between Australian and US institutions, potentially leading to joint clinical trials and the adoption of ProsTIC’s protocols globally. The program’s success is also likely to attract further investment, fueling continued research and development in the field of prostate cancer theranostics. The focus on training the next generation of researchers is a critical long-term strategy, ensuring that Australia maintains its leadership position in this rapidly evolving field. Finally, the increasing use of real-world data from the ProsTIC registry (enabled by collaborations with Novartis) will be instrumental in refining treatment algorithms and improving patient outcomes.